美国成人对艰难梭菌疫苗的偏好
本研究对美国≥50岁成人开展横断面在线调查与离散选择实验,评估其接种艰难梭菌疫苗的意愿及疫苗属性对选择的影响。结果显示,自付费用、疫苗有效性提升和症状严重程度降低对疫苗选择影响最大;多数成人对艰难梭菌疫苗持接受态度,尤其在无自付费用时。
要点
- 在1216名分析对象中,58.0%的选择任务中选择了艰难梭菌疫苗而非不接种。
- 自付费用为零时,估计高达75.0%的人会选择疫苗。
- 自付费用降低(相对重要性=56.1)、疫苗有效性提升(17.7)和症状严重程度降低(10.3)对疫苗选择最重要。
核心结论
- 自付费用、疫苗有效性提升和艰难梭菌感染严重程度降低对疫苗选择影响很大。
- 多数≥50岁成人对艰难梭菌疫苗持接受态度,尤其在自付费用很低或为零时,提示要求保险覆盖疫苗接种且无共付费用可能提高接种率。
- 成人对艰难梭菌认知有限,为医疗保健提供者教育患者关于艰难梭菌感染预防提供了机会。
研究设计与样本
- 横断面在线调查联合离散选择实验,对象为美国≥50岁成人。
- 离散选择实验属性包括有效性、保护持续时间、症状严重程度降低、自付费用、剂次和副作用。
- 离散选择实验包含11个选择任务,每个任务有两个假设疫苗概况和一个不接种选项。
- 采用分层贝叶斯模型估计属性水平偏好权重,并比较部分亚组的属性相对重要性。
- 分析样本为1216名成人。
主要发现
- 在1216名分析对象中,29.9%报告在研究前对艰难梭菌了解一点(20.7%)或了解很多(9.2%)。
- 在所有选择任务中,选择艰难梭菌疫苗(而非不接种)的比例为58.0%。
- 估计自付费用为0美元时,高达75.0%的人会选择疫苗。
- 免疫受损/艰难梭菌感染高风险者(相比非高风险者)更频繁地选择艰难梭菌疫苗。
- 自付费用降低(相对重要性=56.1)、疫苗有效性提升(相对重要性=17.7)和症状严重程度降低(相对重要性=10.3)对疫苗选择最重要;各亚组属性重要性排序一致。
临床怎么用
- 作者认为,要求保险覆盖疫苗接种且无共付费用可能提高接种率。
- 作者认为,成人对艰难梭菌认知有限为医疗保健提供者教育患者关于艰难梭菌感染预防提供了机会。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Clostridioides difficile (C.diff) infection (CDI) causes significant morbidity and mortality among older adults. Vaccines to prevent CDI are in development; however, data on the target population's preferences are needed to inform vaccination recommendations in the United States (US). This study assessed US adults' willingness to receive a C.diff vaccine and examined how vaccine attributes influence their choices. METHODS: A cross-sectional online survey with a discrete choice experiment (DCE) was conducted among US adults aged ≥50 years. DCE attributes included effectiveness, duration of protection, reduction in symptom severity, out-of-pocket (OOP) costs, number of doses, and side effects. The DCE included 11 choice tasks, each with two hypothetical vaccine profiles and an opt-out (i.e., no vaccine). Attribute-level preference weights were estimated using hierarchical Bayesian modeling. Attribute relative importance (RI) was compared between select subgroups. RESULTS: Of 1216 adults in the analyses, 29.9% reported they knew either 'a little' (20.7%) or 'a lot' (9.2%) about C.diff before the study. A C.diff vaccine was chosen 58.0% of the time (vs. opt-out) across choice tasks. It was estimated that up to 75.0% would choose a vaccine when OOP was $0. Those who were immunocompromised/high-risk for CDI (vs. not) more frequently chose a C.diff vaccine. Decreases in OOP costs (RI = 56.1), improvements in vaccine effectiveness (RI = 17.7), and reduction in symptom severity (RI = 10.3) were most important to vaccine choice. The rank ordering of attributes by importance was consistent across subgroups. CONCLUSION: OOP cost, improvements in vaccine effectiveness, and reduction in CDI severity were highly influential to vaccine selection. Most adults aged ≥50 years were receptive to a C.diff vaccine, especially with little-to-no OOP cost, suggesting that mandating insurance coverage of vaccination with no copayment may increase uptake. The limited awareness about C.diff among adults presents an opportunity for healthcare providers to educate their patients about CDI prevention.
引用
- Vietri J, Maculaitis MC, Cappelleri JC, et al. Preferences for a Clostridioides difficile vaccine among adults in the United States. Vaccine. 2024. PMID: 39217776. doi:10.1016/j.vaccine.2024.126261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。